Identify the sessions that will move your strategy forward:
Gain clarity on the latest legal developments affecting your business, from Hatch-Waxman and BPCIA litigation to Section 112 enablement, the UPC, and the Inflation Reduction Act. The agenda helps you prioritise your time and attend the sessions most relevant to your role.
Hear directly from the in-house experts shaping the future of life sciences IP:
With over 50% of the audience coming from in-house legal teams, this event offers rare access to the strategies, challenges and lessons learned by your peers at companies including Regeneron, Teva, Jazz Pharma, Novartis, GSK, and Fresenius Kabi.
Build meaningful connections that support your litigation strategy:
The agenda includes over eight hours of structured networking, including roundtables, receptions and interactive discussions, so you can share ideas and build relationships with originator, generic and biosimilar companies facing similar litigation and exclusivity challenges.
Understand the bigger picture and how to respond to it:
From global case law and biologics litigation to evolving approaches to damages, safe harbor, and AI inventorship, the programme gives you the practical insight you need to adjust your approach and protect your company’s IP assets more effectively.
From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please tick "YES!".
Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].
User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].
For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.
By clicking submit below, you consent to allow Kisaco Research to store and process the personal information submitted above to provide you the content requested.